BENDAMUSTINE Adverse Event: Malignant neoplasm progression
BENDAMUSTINE Adverse Event: Malignant neoplasm progression is one of 4,500 adverse events in the FDATracker dataset. Key details — Primary drug: BENDAMUSTINE; Product category: Drug; Primary reaction: Malignant neoplasm progression.
| Primary drug | BENDAMUSTINE |
|---|---|
| Product category | Drug |
| Primary reaction | Malignant neoplasm progression |
| All reactions | Malignant neoplasm progression; Pancytopenia |
| Seriousness | Serious |
| Patient outcome | Unknown |
| Patient sex | Male |
| All drugs reported | BENDAMUSTINE; RITUXIMAB; PREDNISONE /00044702/; CYCLOPHOSPHAMIDE |
| Reporter country | AU |
| Reporter type | 1 |
| Report date | 20140312 |
| Report ID | 10004203 |
$299/mo
Try FDATracker →